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Abstract
Background: The European Union’s (EU) Clinical Trials Directive was replaced by an EU-Regulation as of 2016. The
policy revision process was subject to a formal impact assessment exercised by the European Commission (EC)
from 2008 to 2014. Following the EU principles of Good Governance, deliberation with stakeholders was an integral
part of this impact assessment and the policy formulation process. Hence, two public consultations (PCs) were held
by the EC in 2009 and 2011, respectively. Various stakeholders contributed and submitted their written input to the
EC. Though often cited in the further revision process, the input gathered in the PC was not communicated with
full transparency and it is unclear how and to what extent the input has been processed and used in the policy
formulation. The objective of this study was an analysis of submissions to both PCs in order to systematically
present what topics have been discussed and which possible policy options have been raised by the stakeholders.
Methods: All written submissions publicly available were downloaded from the EC’s homepage and assessed for
stakeholder characteristics. Thematic text analysis was applied to assess the full text of a random sample of 33% of
these submissions.
Results: A total of 198 different stakeholders from the EU and the United States of America contributed to one or
both of the two PCs. In total, 44 various themes have been addressed that could be clustered under 24 main
themes, including the articulation of problems as well as possible policy solutions to face these problems.
Conclusion: The two PCs on the Clinical Trials Directive were highly appreciated by the various stakeholders and
their input allowed an in-depth view on their particular interests. This input provided a rich source of information
for all stakeholders in the field of clinical trials as well as to the EC’s impact assessment. Although the EC obviously
gathered a large quantity of expert knowledge on practical implications of trials legislation by consulting stakeholders,
it remained unclear how this input was used in the development of the new regulation. For the sake of transparency,
it is recommended that in future PCs the EC uses better standardized methods for a more transparent analysis and
presentation of results.
Keywords: Clinical Trials Directive, Clinical Trials Regulation, European Union, Governance, Deliberation, Public
consultation
Background
Revision of Directive 2001/20/EC
In April 2014, the European Parliament adopted a new
legislative framework for the conduct of clinical trials in
the European Union (EU). The current Directive 2001/
20/EC, most often referred to as the Clinical Trials
Directive (CTD), will be replaced by Regulation EU No
536/201 from the end of May 2016 [1, 2]. In effect since
2004, the CTD has had a deep impact on the planning
and conduct of trials in the EU and internationally,
because of the EU’s prominent economic position [3, 4].
Currently, all clinical trials conducted in EU member
states are regulated following the provisions outlined in
the CTD. Prior to the CTD, legislation mainly fell in the
ambit of the individual member states, creating an
EU-wide patchwork of different regulations. Though
widely seen and accepted as an international standard in
clinical trials, the 1996 International Conference on
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Harmonisation of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use guidelines on
Good Clinical Practice were not applied consistently
throughout the EU. This created a situation where
member states differed in fundamental aspects of the
application and approval procedures for trials, including
risk–benefit analysis, data protection issues, informed
consent, reporting of suspected adverse reactions, etc. In
consequence, differences in the level of patient protec-
tion occurred throughout the EU. Thus, in its aim to
realize a single market for medicinal products, the
European Commission (EC) pursued a harmonized legis-
lative framework governing the conduct of clinical trials
in all member states [5]. However, although the motiv-
ation for the CTD, as briefly outlined above, appeared to
be straightforward, its introduction and subsequent im-
plementation was followed by a huge wave of criticism
[4, 6, 7]. This criticism was raised by a multitude of dif-
ferent stakeholders, and was often more or less focused
on specific parts or articles of the Directive. Some of the
most commonly raised issues in the context of the entry
into force of the CTD concerned an overall inconsistent
implementation of the CTD in the different member
states, leading – among other things – to inconsistencies
in the application and approval procedures. This, in
turn, resulted in an increase of costs, mainly due to an
increased need for human resources to handle the ad-
ministrative workload [8].
Challenged by this critique, the EC recognized a need
for action. Hence, an impact assessment was initiated by
the end of 2008 in order to assess the functioning of the
CTD and to bring forward proposals for further legisla-
tive improvements [9]. Impact assessments are an inte-
gral part of the EC’s efforts to continuously improve the
regulatory environment of the EU, and are highly for-
malized [10, 11]. The formal impact assessment of the
clinical trials legislation was preceded by a stakeholder
conference in October 2007 [12], and further accompan-
ied by the ICREL study (Impact on Clinical Research of
European Legislation), which was conducted in the
course of 2008 [13]. In 2009 and 2011, the Directorate
General for Health and Consumers (DG SANCO) called
stakeholders for public consultations (PCs). The PCs
were each based on consultation documents published
by the EC [14, 15], which described the problems with
the CTD as assessed by the EC and outlined possible
policy options to address them, thereby giving the PCs a
clear structure. Furthermore, stakeholders were asked
for additional comments or suggestions. The impact
assessment finished in 2012 with an extensive two-part
report [16], and was followed by a Commission proposal
for revised legislation on clinical trials. With this, the EC
not only intended to fundamentally overhaul the CTD,
but to replace the whole EU Directive by an EU Regula-
tion [17]. This proposal, however, was far from being a
unanimously-accepted solution to the regulatory prob-
lems faced by the various stakeholders. Strong criticisms
were made [18–20] and further elaboration of the Regu-
lation was necessary before the Parliament finally
adopted the Clinical Trials Regulation (CTR) in April
2014 [1]. A timeline listing the major steps in the revi-
sion of the CTD is presented in Fig. 1.
Stakeholder involvement in the revision process
As mentioned above, the process of revision of the CTD,
and especially the formal impact assessment, was
accompanied by extensive efforts at stakeholder involve-
ment. Obviously, the EC had a considerable interest in
achieving input from all stakeholders in the field of clin-
ical research who were affected by the legislation. The
two PCs seemed to be of particular importance in the
process of revision. The final impact assessment report
frequently refers to points raised by stakeholders during
the PCs. Among other data sources, the stakeholder in-
put served as an empirical basis and a further rationale
for policy choices in the final regulation.
In this context, it is noteworthy that these deliberative
efforts are in line with the overall aim of what is called
Fig. 1 Timeline impact assessment and Revision of Directive 2001/20/EC (see Additional file Additional file 1)
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“Good Governance” as expressed by the EC in a White
Paper in 2001 [21]. The White Paper marked a turning
point in EU policymaking, as it acknowledged the in-
volvement of stakeholders in the policymaking process
as fundamental to the EU’s democratic legitimacy, and
obliged EU institutions to continuously consult with
stakeholders. Therefore, the White Paper can be seen as
a direct consequence of the postulated democratic def-
icit [22]. With that said, it is entirely unsurprising that
the EC consulted stakeholders in the revision of the
CTD. Moreover, at first glance, it seems that every en-
deavour has been made to be most transparent. After
completing the PCs, DG SANCO listed all contributing
stakeholders by name, and in most cases attached the in-
dividual contributions. In addition, a summary report
was compiled and published online for each PC [23, 24].
Nevertheless, the value and utility of these summary
reports are questionable: the EC states that a summary
report “summarizes the responses to the PC document.
In doing so, it not only reflects the majority views, but aims
to give a ‘snapshot’ of the range of responses” [23, 24].
While of course it may seem appropriate and necessary
to offer an overview of the issues addressed in the sub-
missions, summarizing ipso facto runs the risk of losing
information. Since DG SANCO received more than
100 written submissions in each PC, summarizing all
of this input in a document of just over 20 pages seems
rather unsatisfactory. This raises concerns about the
validity of the alleged “snapshot”. In addition, neither
the summary reports nor the impact assessment report
describes the methodology used to analyse the input.
In an amendment to the abovementioned White Paper
on Governance, the EC in 2002 published ‘minimum
standards’ for consultations [25], in which further guid-
ance on stakeholder consultations is given. However,
neither said document, nor any other official EU docu-
ment mention any methods.
Rationale and objectives
Given the reservations expressed above, instead of
merely summarizing the responses, a descriptive ap-
proach seems advisable, providing the reader with an
overview of the full spectrum of topics addressed by
the various stakeholders. Thus, this study aims to ana-
lyse the stakeholder submissions to the PCs and report
on the findings.
To the best of our knowledge, this is the first study
which specifically aims to qualitatively analyse the stake-
holder input expressed to an EC PC. Previous studies in
this field were limited to quantitative assessment of the
number of responses per stakeholder group, and focused
instead on procedural aspects [26–28]. Thus, this study
also contributes to the general field of research on PCs,
with Regulation 536/2014 as a case study [26, 29, 30].
Methods
Material and data preparation
All stakeholders who contributed to the 2009 and/or the
2011 PCs and who are acknowledged by DG SANCO
were listed in alphabetical order, separately for each PC,
including named stakeholders who did not allow the EC
to publish their submissions. The stakeholders were
further grouped into categories, depending on their
institutional background/affiliation. Though the EC itself
already gave an overview of the distribution of
stakeholders’ institutional background/affiliation in the
summary reports, the categorization presented here is
more specific. The EC merely distinguishes stakeholders
as belonging to either hospitals, investigators and ‘non-
commercial’/‘academic’ sponsors, pharmaceutical indus-
try and contract research organizations, competent au-
thorities, Ethics Committees, patient organizations, or
other entities and individuals [23, 24]. Scholars doing
research on the EU’s PCs, however, often use a more
descriptive way to classify stakeholders, mainly distin-
guishing public authorities, associations, companies,
academic researchers and others, thereby differentiating
types of association (e.g. welfare associations, trade
unions, consumer associations, etc.) [26, 27]. Since legis-
lation on clinical trials in general is highly sophisticated
and relevant stakeholders are mainly found in the health
sector, a more specific categorization seemed to better
meet practical needs. Hence, in this study, stakeholders
involved in the two PCs were categorized as follows: (1)
authorities (competent authorities at the local, national
or supranational level, ministries, other agencies and
governmental institutions); (2) non-profit (universities,
non-commercial sponsors, non-commercial research
organizations and associations, and similar); (3) medical
societies (professional associations, medical associations,
and similar); (4) industry (pharmaceutical companies,
clinical research organizations, consultancies and associ-
ations mainly representing commercial actors); (5) indi-
viduals (submissions made by individual persons, not
officially speaking for any other entity); (6) patient and
consumer organizations; (7) Research Ethics Committees
(national/local); and (8) other (not unambiguously fitting
in any other category).
The categorization of stakeholders presented here em-
anates from the attempt to structure all the submissions
in order to get an overview. Sometimes, it was difficult
to assign a stakeholder to one category as they could
arguably have been included in multiple categories. For
practical reasons, we decided to assign each stakeholder
to one category only. Thus, the overview of stakeholders
presented here has a procedural character, and does not
claim to be beyond all question.
Following the descriptive approach in PC research as
presented by Quittkat [26], additional information on
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the individual stakeholders was gathered, such as country
of origin and language used for the written submission.
All published submissions were then downloaded, fol-
lowing the links on DG SANCO’s Homepage.
Thematic analysis
A thematic analysis of the submissions was conducted
[31]. The 2009 and the 2011 PCs were regarded as sep-
arate data sources and therefore analyzed separately.
The approach was the same for both PCs, as follows.
Analysis was restricted to submissions written in either
English or German. Parts of submissions that were not
intended primarily for participation in the PCs were
excluded. For instance, some stakeholders sent their
respective replies to the PC concept paper and attached
some additional documents, which more or less deal
with the CTD (e.g. journal papers, conference presenta-
tions, etc.). These additional documents were not in-
cluded in the analysis because they were often not
focused on the revision of the CTD, and it was often
unclear whether they completely express the opinion/
viewpoint of the respective stakeholder. After this initial
triage, a total of 97 submissions from the first PC and
135 submissions from the second remained. These
formed the basis for two randomized samples of submis-
sions for thematic analysis, one sample of 33% for each
PC. In order to obtain purposive samples, stratified
sampling was conducted, taking into account the distri-
bution of stakeholders among the categories described
above.
From both of these samples, 12 submissions were
analyzed by two researchers independently (HL, JL). All
relevant passages in the submissions were extracted and
coded. A passage was deemed relevant if it (1) made a
clear statement on issues mentioned in the underlying
PC documents published by the EC (e.g. policy options,
problems and solutions outlined in the documents etc.);
(2) described a clear preference for or against policy
options; or (3) introduced additional problems, solutions
or policy options which were not outlined in the PC
documents.
For the sake of practicability, highly technical details
have been excluded from coding (e.g. detailed guidance
on procedural issues, such as the maintenance of the
EudraVigilance databank). Specific examples, simply
used to substantiate an argument already described, have
not been coded. Likewise, commonplace remarks, not
adding any substantial information, were not analyzed
(e.g. remarks that the protection of human subjects in-
volved in clinical trials is always to be considered, which
is clearly a major aim of the CTD, and is unlikely to be
challenged by any stakeholder).
Following established approaches of thematic analysis,
initial codes were subsequently collated into categories,
themes and broader themes [31], which were continually
reviewed to ensure internal coherence of the individual
themes/categories. After checking these submissions,
initial agreement and disagreement in coding were an-
alyzed and discussed to ensure that the coding provi-
sions were met. The remaining submissions (20 from
the 2009 PC and 33 from the 2011 PC) were then an-
alyzed by one researcher alone (HL). The analysis of
the two randomized samples resulted in theoretical
saturation, meaning that no further new themes, add-
ing substantial value to the overall results, could be
identified and no further sampling of contributions
was necessary. A consistency check of the final matrix
of themes was then carried out by two other re-
searchers (JL, DS).




The first PC was open for commentary from October 9,
2009, to January 8, 2010 (13 weeks). One hundred and
six stakeholders submitted responses, of which 99
submissions are publicly available on the DG SANCO
website. Five stakeholders did not want their submis-
sions to be published, and two were partially published.
However, the names of these seven stakeholders are
listed on the website. The second PC was open for com-
mentary from February 9 to May 13, 2011 (13 weeks). A
total of 144 stakeholders submitted responses, of which
139 submissions are publicly available on the DG
SANCO website. Five stakeholders did not want their
submissions to be published (but names are listed). Of
the 144 stakeholders contributing to the second PC, 52
had already participated in the first. Thus, a total of 198
different stakeholders were involved in at least one PC.
Non-profit stakeholders form the largest share of
respondents to both PCs, followed by industry, medical
associations and authorities, respectively. Table 1 shows
the pattern of participation according to the stakeholder
categorization outlined above and the sample used for
thematic analysis.
Results of thematic analysis
The first PC covered 12 broad themes, divided into
narrower themes with further subthemes and categories.
In total, 676 different codes were attributed to text
passages. The second PC covered 10 broad themes,
again divided into narrower themes and categories. Here,
a total of 748 codes were attributed to the submissions.
Table 2 gives an overview of each broad theme with a
short description of its content. Some themes are found
in both PCs, e.g. ‘Trial application, assessment and
approval’, but differ slightly in their content.
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As can be seen in Table 2, by far the greatest number
of comments was made about aspects of trial application
and approval. Besides the sheer number of comments,
no other topic aroused such controversy among the
various stakeholders. For instance, in the 2009 PC, the
EC outlined the possibility of centralization of the ethical
review of trial applications. While some stakeholders
considered this impossible, claiming that the moral and
ethical standpoints of member states are too diverse,
others supported this possibility. Broad theme 1 ‘Trial
application, assessment and approval’ of the 2011 PC
responses contains several sub-themes, namely ‘Coordi-
nated assessment procedure’ (CAP), ‘Central submission
and assessment’, ‘Pre-assessment of trials’, ‘Assessment
bodies’ and ‘Other comments’. The first theme, CAP,
covers 199 comments, thereby representing the most
discussed theme of either PC, and was a policy proposal
outlined by the EC in the consultation document [15].
The rationale of the CAP was to streamline assessment
of clinical trial applications, its main feature being a sin-
gle submission of the trial application and required doc-
uments as well as the provision of a ‘reference member
state’ with the responsibility to process the submissions
to all other member states involved (e.g. those member
states in which the trial is supposed to take place). The
EC further outlined several related proposals, governing
the scope of assessment, procedures in case of disagree-
ments, and the possibility of making the CAP optional.
As the analysis of the sample shows, the CAP was widely
addressed: 24 of the 45 stakeholders in the sample com-
mented on this specific policy option. While the majority
of them expressed a general preference for the CAP,
some responses did raise concerns. Even those who ba-
sically agreed with the EC’s proposal expressed concerns
on specific issues, such as the possibilities in case of dis-
agreements with the assessment. Hence, the thematic
analysis divided the theme into ‘Support for the CAP’
and ‘Rejection of CAP’; at subsequent levels, the themes
further divide into several subthemes, and so on. As a
result, a heterogeneous list of themes, subthemes and
categories emerged, presenting the full scope of stake-
holder input on this specific issue in a systematic
manner.
An in-depth analysis of the different lines of argumen-
tation, reasons and suggested scenarios for even one of
the 12 themes is beyond the scope of this paper. We are
currently working on two in-depth analyses to be
published elsewhere. The full spectrum of themes and
categories can be found in Additional file 1. For further
explanation, or to access the full dataset, including all
subthemes and quotations, please contact the corre-
sponding author (HL).
Discussion
Both PCs were appreciated by the various stakeholders.
As the CTD had been heavily criticized from day one,
the stakeholders took advantage of the opportunity to
engage in the revision process. A mere glance at the
pattern of participation in the PCs gives an interesting
insight into the broad variety of stakeholders, their
background and affiliations. Remarkably, there is no
overrepresentation of commercial interests. This runs
counter to previous findings, which showed that PCs
generally suffer from an imbalance to the disadvantage
of non-commercial stakeholders [26, 27]. In the case of
the CTD, however, academic sponsors and investigators
may have suffered from greater challenges with the
legislative provisions than industrial sponsors. These
challenges mostly derived from an increased administra-
tive workload, which may be harder for local academic
institutions to compensate than for (international) enter-
prises [6, 7, 33]. Thus, it was only natural for the
academic stakeholders to use the PCs to express their
views on the legislation. Relatively few submissions were
made by Patient Organizations and Research Ethics
Committees. While the former may, to some extent, not
Table 1 Stakeholder participation in the 2009 and 2011 public consultations on revision of the Clinical Trials Directive
Public consultation 2009 Public consultation 2011
N Exclusiona Eligible for analysis Included in sample N Exclusiona Eligible for analysis Included in sample
Non-profit 32 3 (P, F, F) 29 10 36 2 (P, P) 34 11
Industry 21 2 (P, P) 19 6 35 3 (P, P, F) 32 11
Medical societies 20 – 20 7 16 – 16 5
Authorities 12 – 12 4 18 1 (P) 17 6
Individuals 8 1 (P) 7 2 9 – 9 3
Research ethics Committees 5 2 (L, L) 3 1 6 2 (L, L) 4 1
Patient organizations 3 – 3 1 12 – 12 4
Other 5 1 (P) 4 1 12 1 (F) 11 4
Total 106 9 97 32 144 9 135 45
aReasons for exclusion: P not published, F wrong/erroneous document uploaded on DG SANCO homepage or document not clearly assignable, L language other
than English or German
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Table 2 List of all broad themes in the 2009 and 2011 public consultation
Codes by stakeholder group
















with regard to trial
application and approval;
options to streamline and
speed up the assessment
238 60 25 90 32 1 25 2 3






comments on the form of
the law and the revision
of accompanying
guidelines













Problems with the current
method of SUSAR
reporting and options for
improvement
56 11 8 10 17 2 8 0 0
5 Third countries Options to improve GCP
compliance in third
countries
43 26 5 8 3 0 1 0 0
6 Regulation of
specific trials




34 13 7 9 2 2 1 0 0
7 General comments Comments on data
presented by the
European Commission;
comments on the EU as a
site for clinical research;
problems with delays in
starting trials, and decline
in number of trials
conducted and subjects
enrolled in trials
34 4 8 9 6 0 6 0 1
8 Risk classification Comments on the
possibility and necessity
of a risk-based approach
to trial legislation




negative effects of the
divergent application of
legislation in the different
member states














25 6 5 4 6 0 4 0 0
12 Trial insurance Comments on aspects
of harmonized trial
insurance
7 4 1 1 0 0 0 1 0
Total codes 676 211 99 186 100 5 61 8 6
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possess sufficient knowledge to reply to the highly
technical consultation documents, the lack of submis-
sions by the latter is remarkable. Article 9 of the CTD
foresees that no clinical trial may start unless a ‘favourable
opinion’ has been issued by an Ethics Committee [2].
One might expect to see considerable participation of



















429 101 36 139 78 29 2 29 15
















82 22 6 21 12 8 0 9 4
4 Insurance Comments on the
responsibility for




52 13 5 17 6 1 0 6 4






24 11 5 5 0 1 0 0 2
6 Third countries Comments on
registration of third
country trials in European
databases and the
assessment and
inspection of trial sites
outside the EU
24 12 0 6 3 0 0 1 2










11 1 0 2 8 0 0 0 0
9 Trials in emergency
situations
Criteria that need to be
met to justify the conduct
of trials in emergency
situations
11 0 3 0 5 3 0 0 0
10 Other comments Several topics, e.g. the
need for more patient-
oriented research
6 0 3 0 0 0 1 1 1
Total codes 748 182 73 224 130 49 6 54 30
Langhof et al. Health Research Policy and Systems  (2016) 14:69 Page 7 of 9
European Ethics Committees in a PC concerning sub-
stantial aspects of their work. For the National Compe-
tent Authorities, this indeed occurred (Table 1). Maybe
the reason can be found in the voluntary basis on
which most Ethics Committees work and the long gaps
between their meetings, both making the drafting of an
agreed submission a difficult task.
With regard to the content of the submissions, virtu-
ally all substantial aspects of the CTD were addressed by
the stakeholders, from the application, assessment and
approval of trials to the indemnification of participants.
The EC decision-makers were offered a rich set of
detailed expert knowledge from various stakeholders.
However, this again raises the question of how the input
was finally used. Though in this study only 33% of all
submissions were analyzed, the quantity of text was
huge. Moreover, almost all participating stakeholders
were experts in the field of clinical trials, but with differ-
ent foci (e.g. for public authorities, juridical and legisla-
tive aspects; for sponsors, procedural aspects), resulting
in highly detailed and technical argumentation, which is
in line with previous studies on PCs [27]. This begs the
question of what resources DG SANCO expended to
process the submissions, given the analytical workload
and the expected utilization of the input. Previous stud-
ies already revealed that PCs tend to increase legislative
duration remarkably. The EC’s lack of sufficient adminis-
trative capacity seems to be the main problem [28].
Moreover, as decision-makers not only need to analyse
the submissions and the individual comments, further
processing would require a kind of rating, e.g. a differen-
tiation between ‘useful’ and ‘less/not useful’. Certainly,
the mere frequency of a favourable comment does not
prove its value [34]. Throughout the summary reports,
the EC assigned the stakeholder commentaries attributes
such as ‘most of them’, ‘only few of them’, etc. [23, 24].
To increase transparency, it would be useful to know
how the EC judges individual comments, and why.
Despite the fact that in EU policymaking processes
PCs are a widespread and frequently-applied instrument
of engaging stakeholders, and even the wider public,
there has been little research on this topic. Quittkat [26]
reports that the EC fails to guarantee inclusiveness of
their PCs and, furthermore, in many cases does not
sufficiently communicate results. In terms of formal
aspects, as set out by the EC in the Minimum Standards,
both PCs analyzed in this case study nearly meet the
formal requirements in full. In addition to granting an
adequate timeline for participation (13 weeks), virtually
all received stakeholder submissions are published on
the DG SANCO website. Unfortunately, transparency
ends when it comes to the reporting of results. The
summary reports and the impact assessment report only
anecdotally refer to stakeholder comments [16, 23, 24].
A first step forward could be the introduction of a trans-
parent, standardized but still practical methodology for
the analysis of stakeholder submissions. Taking into ac-
count the EC’s relatively low administrative capacity
[28], the thematic analysis used for this study could be a
workable and practice-oriented approach [31].
Conclusion
As demonstrated in this study, responses to the two PCs
in the context of the replacement of the Clinical Trials
Directive 2001/20/EC by the Clinical Trials Regulation
EU No 536/2014 provided the EC with a wide range of
input. The relatively high rate of participation suggests
that stakeholders appreciated the opportunity of – to
some extent – active involvement in regulatory activities.
However, up to now it remains unclear to what extent
the input was processed and used by EC in the further
impact assessment and the transition from the Directive
to the Regulation. Further studies are needed to analyse
in detail the possible impact of this stakeholder input on
the revision process, applying a comparative analysis to
the final Regulation and the stakeholder input. This
would not only add to transparency in the particular
policy revision process of the CTD, but would further-
more increase knowledge of the way the EC processes
and uses stakeholder input gathered in PCs in general.
Such systematic impact analyses would also serve as a
basis for practice-oriented recommendations on how to
process PCs in the future. As other studies also reveal
insufficiencies in the conduct of PC [26], a further
elaboration of this specific policy instrument is needed
at EU level. As a first step, the EC should establish
transparent and systematic methods for the analysis of
stakeholder input. The results of this study, and espe-
cially the methods used, might serve as an exemplary
reference. In order to manage the vast amount of quali-
tative input, procedural aspects should also be taken into
account (e.g. carefully balancing the benefit of open
questions against the time needed for analysis).
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